loading page

How to assess pharmacogenomic tests for implementation in the NHS
  • +4
  • Sonali Sanghvi,
  • Robin Ferner,
  • Andrew Scourfield,
  • Robert Urquhart,
  • Sejal Amin,
  • Aroon Hingorani,
  • Reecha Sofat
Sonali Sanghvi
University College London Hospitals NHS Foundation Trust
Author Profile
Robin Ferner
City Hospital
Author Profile
Andrew Scourfield
University College London
Author Profile
Robert Urquhart
University College London Hospitals NHS Foundation Trust
Author Profile
Sejal Amin
University College London Hospitals NHS Foundation Trust
Author Profile
Aroon Hingorani
University College London
Author Profile
Reecha Sofat
University College London

Corresponding Author:[email protected]

Author Profile

Abstract

● Pharmacogenomic testing has the potential to target medicines more effectively towards those who will benefit and avoid use in individuals at risk of harm. ● Implementation of testing into routine practice across a healthcare system requires consideration of the evidence, clinical utility, cost-effectiveness, and operational requirements. ● A national approach to providing pharmacogenomic test recommendations and centralised commissioning will reduce inequity and duplication, but must be transparent and evidence based
04 Dec 2022Submitted to British Journal of Clinical Pharmacology
20 Dec 2022Submission Checks Completed
20 Dec 2022Assigned to Editor
20 Dec 2022Review(s) Completed, Editorial Evaluation Pending
30 Jan 2023Reviewer(s) Assigned
22 Feb 2023Editorial Decision: Revise Major
29 Apr 20231st Revision Received
01 May 2023Submission Checks Completed
01 May 2023Assigned to Editor
01 May 2023Review(s) Completed, Editorial Evaluation Pending
16 May 2023Editorial Decision: Revise Minor
28 May 20232nd Revision Received
28 May 2023Submission Checks Completed
28 May 2023Assigned to Editor
28 May 2023Review(s) Completed, Editorial Evaluation Pending
28 May 2023Editorial Decision: Accept